Atossa Therapeutics Inc. [NASDAQ: ATOS] closed the trading session at $5.37 on 07/02/21. The day’s price range saw the stock hit a low of $5.27, while the highest price level was $6.60. The company report on June 16, 2021 that Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes.
Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced it is set to be added to the Russell 2000 and Russell 3000 Indexes This milestone will take place at the conclusion of the 2021 Russell Indexes’ annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, and June 14, 2021.
“Atossa’s inclusion in both the Russell 2000 and Russell 3000 Indexes present an important opportunity for us to further expand Atossa’s awareness among a broader group of investors, which we expect will also further enhance its liquidity,” said Kyle Guse, Atossa’s CFO and General Counsel.
The stocks have a year to date performance of 465.26 percent and weekly performance of -37.70 percent. The stock has been moved at 465.26 percent over the last six months. The stock has performed 20.95 percent around the most recent 30 days and changed 153.30 percent over the most recent 3-months.
If compared to the average trading volume of 18.14M shares, ATOS reached to a volume of 27924132 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Atossa Therapeutics Inc. [ATOS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATOS shares is $7.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATOS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 1.00 The Price to Book ratio for the last quarter was 3.58, with the Price to Cash per share for the same quarter was set at 1.14.
ATOS stock trade performance evaluation
Atossa Therapeutics Inc. [ATOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -37.70. With this latest performance, ATOS shares gained by 20.95% in over the last four-week period, additionally plugging by 465.26% over the last 6 months – not to mention a rise of 44.35% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 48.44, with the RSI for the last a single of trading hit 41.61, and the three-weeks RSI is set at 52.07 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 4.12, while it was recorded at 6.71 for the last single week of trading, and 2.53 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: An insightful look at the core fundamentals
Return on Total Capital for ATOS is now -72.33, given the latest momentum, and Return on Invested Capital for the company is -88.40. Return on Equity for this stock declined to -88.42, with Return on Assets sitting at -62.18. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.07. Additionally, ATOS Total Debt to Total Capital is recorded at 0.07, with Total Debt to Total Assets ending up at 0.04.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,228,494 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 102.30 and a Current Ratio set at 102.30.
Atossa Therapeutics Inc. [ATOS]: Insider Ownership positions
There are presently around $58 million, or 12.10% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 3,304,140, which is approximately 570.483% of the company’s market cap and around 0.04% of the total institutional ownership; VANGUARD GROUP INC, holding 3,180,565 shares of the stock with an approximate value of $17.08 million in ATOS stocks shares; and BLACKROCK INC., currently with $8.23 million in ATOS stock with ownership of nearly 228940.658% of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 47 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 9,307,336 shares. Additionally, 6 investors decreased positions by around 72,138 shares, while 1 investors held positions by with 1,422,952 shares. The mentioned changes placed institutional holdings at 10,802,426 shares, according to the latest SEC report filing. ATOS stock had 36 new institutional investments in for a total of 1,412,759 shares, while 3 institutional investors sold positions of 900 shares during the same period.